| Literature DB >> 30983804 |
Priya Datta1, Jagdish Chander1, Varsha Gupta1, Gursimran Kaur Mohi1, Ashok K Attri2.
Abstract
AIMS: Diabetic foot ulcer is a dreaded complication of diabetes. Diabetic foot ulcer patients are often infected with multidrug resistant organism (MDRO) due to chronic course of the wound, inappropriate antibiotics treatment, frequent hospital admission, neuropathy, nephropathy, and peripheral vascular disease.Entities:
Keywords: Diabetic foot ulcer; multidrug resistant organisms; risk factors
Year: 2019 PMID: 30983804 PMCID: PMC6437817 DOI: 10.4103/JLP.JLP_106_18
Source DB: PubMed Journal: J Lab Physicians ISSN: 0974-2727
Antimicrobial susceptibility pattern of various bacterial isolates from diabetic foot ulcer
| Antibiotics | ||||||||
|---|---|---|---|---|---|---|---|---|
| Cefepime | 18 (47) | 10 (67) | 1 (17) | 4 (22) | 3 (60) | 3 (43) | - | - |
| Ceftazidime | 21 (55) | 13 (87) | 3 (50) | 4 (22) | 3 (60) | 3 (43) | 5 (33) | 3 (60) |
| Ceftriaxone | 23 (60) | 15 (100) | 4 (67) | 4 (22) | 3 (60) | 4 (57) | 5 (33) | 3 (60) |
| Cefoxitin | 20 (53) | 8 (53) | 3 (50) | 3 (17) | 4 (80) | 5 (71) | - | - |
| Amoxyclav | 24 (63) | 11 (73) | 4 (67) | 3 (17) | 2 (40) | 5 (71) | - | - |
| Ceftazidime/clavulanic acid | 16 (42) | 9 (60) | 2 (33) | 3 (17) | 1 (20) | 3 (43) | - | - |
| Tobramycin | - | - | - | - | - | - | 5 (33) | 3 (60) |
| Ciprofloxacin | 17 (45) | 9 (60) | 5 (83) | 6 (33) | 3 (60) | 5 (71) | 8 (53) | 5 (100) |
| Piperacillin/tazobactam | 16 (42) | 7 (47) | 2 (33) | 3 (17) | 2 (40) | 4 (57) | - | - |
| Amikacin | 15 (39) | 12 (80) | 2 (33) | 3 | 1 (20) | 3 (43) | 7 (46) | 2 (40) |
| Imipenem | 5 (13) | 3 (20) | 1 (17) | 1 (5) | 1 (20) | 1 (14) | 3 (20) | 2 (40) |
| Aztreonam | - | - | - | - | - | - | 5 (33) | 3 (60) |
| Colistin | - | - | - | - | - | - | 2 (13) | 0 |
| Polymyxin | - | - | - | - | - | - | 1 (7) | 0 |
Comparison of various risk factors in diabetic foot patients harboring multidrug resistant organisms and nonmultidrug-resistant organisms pathogens
| Risk factors | MDRO ( | Non-MDRO ( | OR (95% CI) | |
|---|---|---|---|---|
| Age (years) | ||||
| <50 | 20 | 12 | 1.5 | 0.36 |
| 50-60* | 36 | 32 | 1 | |
| Sex | ||||
| Male | 40 | 34 | 0.7 | 0.50 |
| Female* | 16 | 10 | 1 | |
| Type of diabetes | ||||
| Type 1 | 6 | 12 | 0.4 | 0.12 |
| Type 2* | 50 | 32 | 1 | |
| Duration of diabetes (years) | ||||
| <10 | 7 | 8 | 1 | 0.02 |
| 10-19 | 18 | 11 | 4.2 | |
| >20* | 31 | 25 | 3.1 | |
| Duration of ulcer (months) | ||||
| ≤3 | 18 | 18 | 1.4 | 0.30 |
| >3 | 38 | 26 | 1 | |
| Size of ulcer (cm2) | ||||
| <4 | 12 | 18 | 1 | 0.03 |
| >4 | 44 | 26 | 2.5 | |
| Grading of ulcer | ||||
| Grade 1 | 13 | 20 | 1 | 0.19 |
| Grade 2 | 26 | 11 | 3.6 | |
| Grade 3 | 17 | 13 | 2 | |
| Complication | ||||
| Nephropathy | 8 | 4 | 0.7 | 0.20 |
| Neuropathy | 42 | 38 | 0.4 | |
| PVD | 6 | 2 | 1 |
MROD = Multidrug-resistant organisms, CI = Confidence interval, PVD = Peripheral vascular disease, OR = Odds ratio